Treatment of Metformin Decreases the Risk of Varicose Vein: A Mendelian Randomization Study

Abstract

Background Varicose vein is a common illness of the vascular system which affects life quality and social function of patients. We aimed to assess the causality between metformin and varicose vein using a two-sample Mendelian randomization（MR）analysis based on genome-wide association study (GWAS) summary data.Methods Twenty-five single nucleotide polymorphisms (SNPs) were selected from the GWAS summary data from Neale Lab and MRC-IEU Consortium available on the MR-base platform. Inverse variance weighted (IVW), MR-egger method, weighted median method and weighted mode were adopted. Results were evaluated by pleiotropy test using an Egger regression method and sensitivity analysis preforming a leaving-one-out (LOO) method. Analyses were performed using R package “TwoSampleMR”.Results The result of IVW method showed that one SD increased treatment of metformin was linked with approximately 10% lower risk of varicose vein (OR,0.90; 95%CI, 0.85-0.96; P, 6.99e-04). It was similar to that measured by other methods in the aspect of effect size and direction. There is no evidence to supporting genetic pleiotropy in the MR-Egger regression method (intercept=2.5e-04, P=0.33). No single SNP was detected to be strongly driving the overall causal effect in a LOO sensitivity analysis. The genetically predicted treatment of metformin was negatively casually associated with varicose veins.Conclusions This study suggested that treatment of metformin was a casual protective factor of varicose vein. Further researches are required to confirm our findings and explore the potential mechanisms of metformin on varicose vein.